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Abstract
Low molecular weight heparins (LMWH) have remained the most favorable form of heparin in 
clinics since 1990s’ owing to its predictable pharmacokinetic properties. However, LMWH is 
mainly eliminated through kidney, thus limits its use in renal-impaired patients. In addition, the 
anticoagulant activity of LMWH is only partially neutralized by protamine. LMWH is obtained 
from a full-length, highly sulfated polysaccharide harvested from porcine mucosal tissue. The 
depolymerization involved in LMWH production generates a broad size distribution of LMWH 
fragments (6-22 sugar residues). This, combined with the various methods used to produce 
commercial LMWHs, result in variable pharmacological and pharmacokinetic properties. An 
alternative, chemoenzymatic approach offers a method for the synthesis of LMWH that has the 
potential to overcome the limitations of current LMWHs. This review summarizes the application 
of a chemoenzymatic approach to generate LMWH and the rationale for development of a 
synthetic LMWH.
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History of heparin
Heparan sulfate is a polysaccharide-based natural product, widely expressed on mammalian 
cell surfaces and in the extracellular matrix. Its contribution to the number of biological 
processes, including the embryonic development, inflammatory response, bacterial/viral 
infection and blood coagulation has been previously summarized [1, 2]. Heparin, highly 
sulfated form of heparan sulfate, is a powerful anticoagulant that has been clinically used for 
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almost a century. Despite the development of new anticoagulants in recent years, heparin 
remains the drug of choice in several medical conditions [3]. Heparin was originally isolated 
in 1916 from canine liver cells by Jay McLean and William Howell. The name heparin 
comes from the Greek word “hepar” for liver, the organ from which heparin was first 
isolated [4]. During the early years (1930-1950) of heparin manufacturing, a number of 
different tissue sources (e.g. dog liver, bovine liver and lung) were evaluated for large-scale 
production. Over the last 3 decades, porcine intestinal tissue has become the major source 
for heparin [5].
The heparin extraction process starts with boiling porcine intestines, to collect mucosal 
membranes and then drying them to obtain crude heparin extracts. Heparin extracts are then 
combined and purified before being formulated as an injectable drug [6]. Heparin exists in a 
heterogeneous form. The molecular weight (MW) for heparin ranges from 3,000-30,000 
Daltons [7]. Only one third of heparin polysaccharide chains display anticoagulant 
properties implying that a specific sequence in the polysaccharide chain is required for this 
activity [8, 9]. During 1970-1980, a depolymerized form of heparin was introduced, namely, 
low molecular weight heparin (LMWH) [10]. Thus, the full-length heparin is referred to as 
unfractionated heparin (UFH). LMWH has a smaller molecular size range resulting in 
greater bioavailability and longer half-life compared to UFH [10, 11] (Table 1). These 
properties have made LMWH more attractive in clinical use, primarily in the outpatient 
setting. LMWH has the added benefit of conferring a lower risk for heparin-induced 
thrombocytopenia (HIT) than UFH [12].
Heparin prevents clot formation through the pentasaccharide domain
A robust procoagulant response is essential for hemostasis, but excessive activation of 
coagulation can result in thrombosis. The coagulation cascade can be divided into the 
extrinsic, intrinsic and common pathways. Small amounts of thrombin generated by the 
extrinsic pathway are amplified via the intrinsic pathway resulting in the production of large 
amounts of thrombin. Subsequently, thrombin cleaves fibrinogen to fibrin resulting in clot 
formation [13]. Antithrombin (AT) is the endogenous inhibitor of coagulation proteases that 
primarily inactivates thrombin and factor Xa (FXa) [14, 15]. Heparin has a unique 
pentasaccharide structure within its polysaccharide chain that allows interaction with AT 
[16, 17]. Upon binding to AT, heparin induces a conformational change in AT resulting in 
1000-fold enhancement of FXa and thrombin inhibition (Figure 1) [17, 18]. The inhibition 
of FXa depends exclusively on the presence of the specific pentasaccharide unit while the 
anti-thrombin activity requires the extension of at least 18 sugar residues [15] in addition to 
the presence of the pentasaccharide unit [19]. The landmark work by Walenga and 
colleagues demonstrated that specific inhibition of FXa by a synthetic pentasaccharide 
results in antithrombotic activity [20]. This finding opened a new avenue of the 
antithrombotic drug development.
Clinical applications of commercially available heparins
Commercial heparins are categorized into three forms corresponding to their average 
molecular weight: UFH (MWavg ~14,000), LMWH (MWavg ~ 3,500-6,000), and the 
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synthetic pentasaccharide, fondaparinux (MW 1508.3) [21]. UFH and LMWH are 
manufactured from animal sources whereas the pentasaccharide is produced by chemical 
synthesis [22, 23]. LMWH is derived from UFH by chemical and enzymatic 
depolymerization [5], resulting in smaller size polysaccharide fragments [5].
The unique pharmacokinetic profiles of the three forms of heparin have resulted in certain 
formulations being preferred over others in clinical practice based on the indication [3]. 
UFH is the oldest form of heparin possessing potent anticoagulation effect which is rapidly 
and efficiently reversed by an antidote, protamine. Although UFH has several clinical 
advantages, including the prevention and treatment of venous and arterial thromboembolism, 
the wide range molecular weight distribution of UFH is associated with differences in 
bioavailability between individual patients, thus making its anticoagulant activity less 
predictable [24]. This necessitates routine monitoring in patients receiving UFH to ensure 
appropriate dosing. Furthermore, 2-3% of patients treated with UFH develop HIT, a 
potentially life-threatening complication of heparin treatment [25]. Thus, UFH is better 
suited for use in hospitalized patients under close monitoring. UFH is commonly prescribed 
for patients undergoing cardiopulmonary bypass or hemodialysis because of its rapid onset 
of action [26] and short half-life. An added advantage is that clearance of UFH is largely 
independent of renal function making it safe for use in patients with renal dysfunction [27]. 
LMWH offers a number of advantages over UFH including predictable bioavailability 
through subcutaneous administration [28], a longer plasma half-life [29], and lower 
incidences of HIT [27]. LMWH has also been associated with a more favorable bleeding risk 
(UFH = 2.3%, LMWH =1.4%) [30]. These advantages make LMWH a good choice for 
outpatient treatment and prophylaxis of venous thromboembolism, and the management of 
patients with acute myocardial infarction and unstable angina [3]. LMWH however does 
dependent largely on renal function for clearance and should therefore be avoided or used 
with caution in patients with compromised renal function [27]. Fondaparinux has a similar 
profile to LMWH but several case reports suggested that it may be safe to use in patients 
with HIT [3, 31, 32]. In addition, Kang and colleagues reported that fondaparinux has 
similar effectiveness and safety as argatroban and danaparoid in patients with suspected HIT 
[33]. Currently, LMWH is the most commonly prescribed form of heparin.
The need for development of a synthetic LMWH
Dangers of dependence on animals for the supply chain
The 2007-2008 worldwide heparin crises indicated that heparin production is vulnerable to 
contamination and adulteration [34, 35]. Structurally similar to heparin, oversulfated 
chondroitin sulfate (OSCS) is a semi-synthetic material that was intentionally made to 
adulterate crude heparin for economic gain by the manufacturers [36, 37]. The 
contamination of heparin with OSCS caused allergic reactions and death in over a hundred 
patients receiving UFH [38]. This incident has raised concerns over the safety and reliability 
of animal-sourced UFH and LMWH [37, 39]. Although the newly implemented heparin 
monograph [40] safeguards against the possibility of future OSCS contamination in heparin 
products, concerns remain regarding risk for contamination due to the source and 
methodologies involved in heparin production. Further, unforeseeable events such as 
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widespread disease outbreaks affecting the animal source (e.g. swine flu outbreak) can 
significantly affect drug manufacturing and availability. The shortcomings of animal-sourced 
heparin production have provoked researchers to seek alternative methods to produce 
heparin.
Variability in pharmaceutical profile between different LMWHs
Commercially available LWMHs differ in size distribution with MW ranging from 
3,500-6,000. This is the result of differences in methods used to depolymerize full-length 
UFH to produce LMWH. For example, enoxaparin (MWavg ~4500) is produced using 
benzylation followed by alkaline hydrolysis; dalteparin (MWavg ~ 6000) is derived from 
controlled nitrous acid depolymerization; and tinzaparin (MWavg ~6500) is prepared by 
controlled heparinase digestion [41].The polydispersity in chain length may affect metabolic 
clearance because short oligosaccharides require renal clearance while larger 
polysaccharides are eliminated by the liver [42]. Furthermore, a structural characterization 
study on these three LMWHs demonstrated that the depolymerization methods potentially 
damage the pentasaccharide region of the LMWHs, thus reducing their anticoagulant 
potency [43].
In addition, depended on the molecular weight, heparins can differentially affect the function 
of tissue factor pathway inhibitor (TFPI) which is a natural anticoagulant inhibiting tissue 
factor /FVIIa complex via FXa–dependent manner. It has been shown that longer chain 
polysaccharide release more TFPI from the surface of endothelial cells compared to the 
lower molecular weight [44]. Thus, different LWMH brands possessing the heterogeneity of 
saccharide chain length may variably affect TFPI release.
As mentioned earlier, the requirement of the saccharide chain length to exert the inactivation 
of FXa and FIIa dictates a ratio between the anti-FXa and anti-FIIa activities (anti-FXa/anti-
FIIa ratio). A full length UFH efficiently inhibits both FXa and FIIa resulting in the anti-
FXa/anti-FIIa ratio of 1:1. LMWH, on the other hand, predominantly inhibits FXa resulting 
in a larger ratio of anti-FXa/anti-FIIa e.g. enoxaparin (4-16 sugar residues), 3.9:1; dalteparin, 
2.5:1 (8-22 sugar residues) and Tinzaparin (4-18 sugar residues), 2:1. A majority of the 
smaller LMWH fragments presented in LMWH are only capable of inhibiting FXa. Thus, 
different LMWHs produced from various depolymerization procedures differ in their anti-
FXa/antiFIIa ratios due to their polydispersity. Consistent with that, the U.S. FDA indicates 
that none of the LMWH product brands are interchangeable [45].
The lack of an effective antidote for LMWH
The U.S. FDA approved protamine for use as an antidote for UFH in the event of bleeding 
complications [46]. Protamine is a highly basic protein predominantly composed of arginine 
residues, displaying positive charge under physiological pH. The polycationic structure of 
protamine interacts with highly negatively charged heparin. Protamine efficiently reverses 
the anticoagulant activity of UFH, however only partially neutralizes LMWHs [47, 48]. The 
affinity for the interaction between protamine and heparin depends on negative charge 
density and the length of the polysaccharide chains [49]. Thus, UFH is more efficiently 
neutralized by protamine than LMWH due to its longer chain size. In addition to chain size, 
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the polydispersity of LMWH also contributes towards efficacy of neutralization by 
protamine. For example, short chain LMWHs (≤ decasaccharides) that demonstrate anti-FXa 
activity are too short to interact with protamine. As such, larger oligosaccharides in LMWH 
can be neutralized by protamine while smaller fragments still display anticoagulant activity. 
This explains why protamine only partially neutralizes LMWHs.
Dependence of LMWH on renal function
UFH is safe in patients with renal impairment because it is metabolized predominantly by 
the liver whereas fondaparinux is contraindicated as it is cleared primarily through the 
kidney [50]. The obvious contrast in clearance between UFH and fondaparinux suggests that 
the size of heparin fragments plays a key role in the elimination process. A scavenger 
receptor, namely stabilin-2, highly expressed in the sinusoidal endothelial cells of the liver, 
is primarily responsible for the clearance of heparin [51]. Stabilin-2 was identified as a 
systemic clearance receptor for UFH and a portion of LMWH [52]. The investigation on 
stabilin-2 receptor revealed that the scavenger receptor recognizes a minimal length of at 
least 10 sugar residues and the presence of hydroxyl group at C3 position of N-sulfo 
glucosamine (GlcNS) residue within the heparin chain [42]. While LMWHs can be used in 
patients with mild to moderate renal impairment with close monitoring and dose 
adjustments, there is considerable risk for decreased clearance and development of bleeding 
complications associated with supratherapeutic plasma drug levels [53].
Development of an enzyme-based method to synthesize heparin
Biology of heparin synthesis
Heparin is found in mast cell granules and interacts with histamine, proteases and other 
inflammatory mediators [54]. The heparin polysaccharide consists of a disaccharide 
repeating unit of either glucuronic acid (GlcA) or iduronic acid (IdoA) and glucosamine 
(GlcN) residues. The disaccharide unit is capable of carrying sulfo groups (Figure 2) [55].
Biosynthesis of heparin occurs in the endoplasmic reticulum and the Golgi and involves a 
series of specialized enzymes. Generally, the pathway consists of three phases: initiation, 
polymerization and modification of the chain. The initiation phase involves formation of a 
linker that tethers to a serine residue of serglycin, a core protein presented in the mast cell 
(Figure 3). Then, chain polymerization takes place by formation of a copolymer of N-
acetylglucosamine (GlcNAc) and GlcA, and this forms the backbone of heparin. This chain 
elongation process is driven by two polymerases known as exostosin glycosyltransferase 1 
(EXT 1) and EXT 2 [56]. The unmodified polysaccharide backbone subsequently undergoes 
chain modification by a series of sulfations and epimerization. The first modification step is 
N-sulfation of GlcNAc residues by N-deacetylase/N-sulfotransferase (NDST), which is a 
critical step for subsequent modification. NDST has two functions: removal of the acetyl 
group (N-deacetylase activity, NDase) and installation of an N-sulfo group (N-
sulfotransferase activity, NST) [57]. After N-sulfation, C5-epimerase (C5-epi) following by 
2-O-sulfation take place. C5-epi converts the D-glucuronic acid (GlcA) to L-iduronic acid 
(IdoA) [58]. 2-O-sulfotransferase catalyzes the transfer of a sulfo group to the 2-O-position 
of either IdoA or GlcA, but preferentially to the IdoA residue [59]. The addition of a sulfo 
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group at the 6-OH of GlcN is modified by 6-O-sulfotransferases [60]. Lastly, 3-O-
sulfotransferases add a sulfo group at the 3-OH of GlcN (39), and this is critical for AT 
binding and anticoagulant activity (Figure 3) [61, 62].
Creation of synthetic heparin polysaccharides
Synthesis of the pentasaccharide is purely chemical. It is extremely difficult, if not 
impossible, to synthesize polysacharides in the size range of LMWH using this method. 
However, the utilization of biosynthetic enzymes offers an alternative strategy to synthesize 
heparin oligosaccharides. These enzymes have high regioselectivity towards their substrates 
thereby eliminating the need for protecting groups in the chemical synthesis. This in turn 
drastically shortens the synthetic route and improves the product yield [21].
Heparin biosynthetic enzymes have been extensively studied and characterized [63]. Several 
crystal structures of heparin biosynthetic enzymes are available providing information 
necessary for designing heparin structures with specific biological functions [64-66]. It is 
now feasible to alter substrate specificity and synthesize certain structures that cannot be 
obtained from the wild type proteins [67]. Further, the sequence of enzymatic modifications 
can be altered making it feasible to create the exact structure of a specific, desired target 
compound. To date, the majority of these biosynthetic enzymes have been expressed in 
Esherichia Coli (E. coli) [68]. In 2011, the research groups of Liu and Linhardt successfully 
utilized a chemoenzymatic method to synthesize an ultra low molecular weight heparin with 
equivalent anticoagulant potency to that of fondaparinux [69].
Strategies for chemoenzymatic synthesis of heparin
The key components for the chemoenzymatic synthesis of heparin are enzymes, sugar 
substrates and a sulfo donor. Most of the biosynthetic enzymes have been characterized [67]. 
However, recombinant form of certain enzymes are difficult to obtain. Furthermore, some 
natural sugar nucleotides are not compatible with the chemoenzymatic synthesis strategy 
therefore unnatural nucleotide sugars are required. Finally, the commercial sulfo donor is 
prohibitively expensive for a large scale synthesis. The following strategies have been 
developed to overcome these problems.
Altering biosynthetic enzymes
Although several mammalian heparin biosynthetic enzymes have been successfully 
expressed in the bacterial expression system, certain enzymes e.g. EXT 1 and EXT 2 cannot 
be expressed in E. coli. To overcome this problem, bacterial glycosyltransferases from the E. 
Coli K5 strain (N-acetyl glucosaminyl transferase, KfiA) [70] and heparosan synthase 2 
from Pasteurella multocida (pmHS2) [71, 72] are utilized in the synthesis of heparin 
backbone [73]. The bacteria produce extracellular carbohydrate capsule consisting of a 
disaccharide unit that is identical to the unmodified heparin backbone suggesting the use of 
bacterial glycosyltransferase counterparts.
NDST is a key enzyme in heparin biosynthesis as previously discussed. However, NDST is 
not suitable for the chemoenzymatic synthesis because of two reasons: first, NDST is a large 
protein with more than 800 amino acid residues, and is difficult to express in E. coli in high 
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levels. Second, the conversion of GlcNAc to GlcNS residue by NDST has a specific pattern, 
depending on the isoform [74]. Thus, the use of NDST does not allow the freedom to vary 
the position of the GlcNS residue in a heparin product. As mentioned previously, N-
sulfotransferase (NST) is the C-terminal of NDST, consisting of only N-sulfotransferase 
activity. NST is only 260 amino acid residues long, and is expressed in E. coli at a very high 
level [65]. Therefore, using only the NST domain with the modified glucosamine substrate, 
allows the completion of the N-sulfation step and overcomes the limitations of NDST.
Modifying the sugar substrate
Formation of a glycosidic linkage in the core backbone of heparin requires uridine 
diphosphate sugar substrates: UDP-GlcNAc and UDP-GlcA. In the N-sulfo addition step by 
NDST, NDase removes the N-acetyl group and converts GlcNAc (CH3CONH) to the free 
amino group (GlcNH2). NST adds a sulfo group to GlcNH2 resulting in GlcNS 
(GlcNHSO3). Because NDST is not available, an alternative method using NST and an 
unnatural uridine diphosphate sugar substrate were used to introduce the GlcNS residues. 
Here, the presence of GlcNH2 substrate is required for the sulflation by NST. The 
implementation of an unnatural UDP-N-trifluoroacetyl glucosamine (UDP-NTFA) serves as 
an analog of UDP-GlcNAc [75, 76] as they are structurally similar [77]. The GlcNTFA 
residue is introduced into the heparin core backbone by glycosyltransferases both KfiA and 
pmHS2. The N-trifluoroacetyl group (CF3CONH) from the GlcNTFA residue can be 
removed by a basic condition (lithium hydroxide) yielding GlcNH2 residue (Figure 4).
Preparing in-house sulfate donor
In addition to polysaccharide backbone synthesis, sulfate modifications crucially dictate 
biological activity of heparin. The sulfation steps by multiple sulfotransferases require a 
sulfate donor known as 3’-phosphoadenosine 5’-phosphosulfate (PAPS). PAPS is expensive 
and the availability of PAPS is a key determinant of cost-effectiveness when considering 
large-scale synthesis for clinical use. This limitation has been addressed by the synthesis of 
PAPS using an enzymatic approach in a one-pot format using ATP sulfurylase (from 
Kluyveromyces lactis), APS kinase (from Penicillium chrysogenum) and pyrophosphatase 
(from E.coli). Bacterial expression of all three enzymes yielding crude extracts are 
efficiently enough to convert ATP and sulfate to PAPS in a gram scale [78].
Alternatives for low molecular weight heparin production
It has been well established that heparin binds to a number of biological proteins resulting in 
various pharmacological effects. Heparin compound obtained from natural sources is 
heterogeneous with a number of drawbacks that have already been discussed. Recent 
technological advances in carbohydrate chemistry (both chemical and enzymatic synthesis) 
have made development of synthetic LMWH for clinical applications feasible.
Non-enzymatic synthesis of larger heparin molecules remains a challenge. Protecting and 
de-protecting steps of reactive hydroxyl groups are essential for a chemical synthesis of 
carbohydrate. In addition, the stereoselectivity is critically important. The Gardiner research 
group successfully synthesized a lead compound in gram-scale (12 sugar residue heparin-
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related compound) by constructing a starting disaccharide that is used as a precursor 
building block for repeated elongation cycles [79, 80]. The resulting product is useful for 
pharmacokinetic and metabolic studies in vivo.
M118 is an improved LMWH that was rationally designed to circumvent the polydispersity 
of commercial LMWHs. M118 has a high potency with reduced polydispersity [81] that 
results from a stepwise manufacturing process starting from isolation of high potency UFH. 
The isolated UFH is depolymerized by a patented heparin lyase mutant which shortens UFH 
into LMWH fragments while the AT-binding domain largely remains intact. The fragments 
are further selected for a portion of high anti-FXa and anti-thrombin activities. The resulting 
LMWH displays superior anticoagulant activity than the parent UFH (and other LMWHs) 
due to the decrease in polydispersity. However, M118 is still derived from animal-source 
material.
In addition to the development of M118, our group created a simple and rapid enzymatic 
method to produce a LMWH that has a narrow size distribution [82]. The method involves 
use of a dual function pmHS2 to simultaneously add GlcN and GlcA to a starting saccharide 
precursor in a one-pot enzymatic reaction. The one-pot synthetic format limits the size 
distribution of the resulting sugar backbone in a range of 8-14 sugar residues which is 
narrower than that of commercial LMWHs (6-22 sugar residues). The sugar backbones 
produced by the controlled enzymatic reaction were further subjected to sulfo modifications 
yielding a narrow size distribution LMWH with potent anti-FXa activity. This enzymatic 
approach eliminates need for animal source material and improves both polydispersity and 
anticoagulant potency.
A new homogeneous, reversible LMWH
A new synthetic, homogeneous LMWH was designed such that it had the following 
beneficial properties: potent anticoagulant activity, hepatic clearance, and effective 
neutralization with protamine. Recently, we synthesized a series of homogeneous LMWHs 
that were composed of 6, 8, 10, or 12 sugar residues (6mer, 8mer, 10mer and 12mer) (Figure 
5A) [83]. All of these synthetic LMWHs were structurally designed to carry the 
pentasaccharide motif for AT binding. The initial step in the synthesis was building a sugar 
backbone. We employed a commercially available monosaccharide, 1-O-(para-nitrophenyl)-
glucuronide (GlcA-pNP), as the starting monosaccharide. Two bacterial glycosyltransferases 
(KfiA and pmHS2) were used in a step-wise elongation process. Placement of sulfo groups 
at N- and O-positions were driven by the specific sulfotransferases responsible for these 
positions while altering of the GlcA configuration was catalyzed by C5-epimerase (Figure 
5B).
The pharmacological properties of these synthetic LMWHs were investigated both in vitro 
and in vivo in comparison to UFH and enoxaparin [83]. All of the synthetic LMWHs 
showed superior potency in the anticoagulant activity in comparison to UFH and enoxaparin. 
We probed the binding of these LMWHs to the stabilin-2 receptor (systemic clearance 
receptor for UFH and a portion of LMWH [52]) both in vitro and in vivo. Larger LMWHs 
(10mer and 12 mer) were internalized by stabilin-2 and retained in the liver, while the 
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smaller LMWHs (6mer and 8mer) showed low binding to the receptor. We next determined 
the ability of protamine to neutralize the synthetic LMWHs. The smaller LMWHs (6mer, 
8mer and 10 mer) displayed fairly low sensitivity to protamine neutralization. Further, the 
anticoagulant activity of the larger LMWH (12mer) was still not fully reversible by 
protamine. Therefore, we further modified the 12mer by adding an extra sulfo group to 
obtain S12mer (Figure 5A). The S12mer demonstrated the same protamine reversibility as 
UFH. These finding were confirmed in an ex vivo mouse model. Finally, in vivo studies 
using a mouse-tail-clip bleeding model showed that protamine reduced the prolonged 
bleeding time induced by the S12mer (77).
Our data suggested that protamine only neutralized LMWH fragments larger than 10 sugar 
residues. Commercial LMWH is a mixture of LMWH fragments with a broad size 
distribution and this wide range in polymer size is associated with variable affinity towards 
protamine. This explains the partial protamine neutralization observed with commercial 
LMWHs. The excellent sensitivity toward protamine neutralization shown by the S12mer 
suggests both size of the sugar backbone and the sulfation pattern contribute to the 
sensitivity toward protamine neutralization.
Conclusion
The advancement in understanding the substrate specificity of heparin biosynthetic enzymes 
is critically important to conduct successful enzymatic synthesis. An enzymatic approach 
circumvents the difficulty in heparin synthesis and provides an alternative to synthesize the 
complex, carbohydrate containing molecules that reach the limit of the organic synthesis. 
The use of biosynthetic enzymes not only provides a high regio- and stereo-selectivity for a 
formation of glycosidic bond but also solves the problems of protection and de-protection 
steps required for chemical synthesis.
It has been established that a sulfation pattern as well as the size of heparin fragments are 
key factors contributing to the interaction between heparin and heparin-binding proteins 
[84]. Other therapeutic applications of heparin have been extensively studied e.g. anti-
inflammatory property. With the well-developed enzymatic approach, custom designed 
heparin, without anticoagulant activity to avoid the hemorrhagic side effect, can be achieved. 
The development of synthetic version of heparins not only eliminates the disadvantages and 
risks of using animal derived-medicine; it also supports further biological studies of heparin 
and its related compounds.
The production of synthetic heparin in laboratories has already reached to gram scale, a 
nearly 500,000-fold increase compared with the first synthesis published in 2002 [85]. This 
improvement is the result of more efficient enzyme expressions and the higher efficiency in 
the synthesis of enzyme co-factors. Although the cost of synthetic heparins synthesis is still 
higher than the production cost of natural heparins, further development of the 
chemoenzymatic approach should result in cost-effective products, accelerating the 
modernization of LMWH drugs.
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Figure 1. A chemical structure of the pentasaccharide motif of heparin polysaccharide
Heparin binds to antithrombin through a pentasaccharide region leading to the inhibition of 
Factor Xa (FXa). The Inhibition of FXa requires the unique sequence of sugar shown as A-
B-C-D-E. Heparin polysaccharide that contains at least 18 sugar residues can form a 
complex with thrombin and inactivates it.
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Figure 2. Disaccharide repeating unit of heparin
The disaccharide unit is capable of carrying sulfo groups. The GlcN residue can be sulfated 
at the N-, 3-O- and 6-O- positions while GlcA and IdoA only carry a sulfo group at the 2-O-
postion.
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Figure 3. Heparin biosynthesis
Two polymerases, EXT1 and EXT2, are responsible for building the non-sulfated and non-
epimerized backbone polysaccharide consisting of the disaccharide repeating unit of GlcA 
and GlcNAc linked by a glycosidic linkage, where GlcNAc presents N-acetylated 
glucosamine, GlcA presents glucuronic acid. N-deacetylase/N-sulfotransferase (NDST) is a 
dual function enzyme: it removes an acetyl group from a GlcNAc residue, displaying 
deacetylase activity (NDase), then transfers a sulfo group to the deacetylated glucosamine 
residue to form an N-sulfo glucosamine (GlcNHSO3) residue, displaying N-sulfotransferase 
activity (NST). C5-epimerase (C5-Epi) converts a GlcA residue to an IdoA residue. 
Sulfotransferases co-functioning with a sulfo donor, 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS), add sulfo groups to their respective positions. 2-O-sulfotransferase (2-OST) adds 
sulfo groups at the 2-OH position of both GlcA and IdoA while 6-O-sulfotransferase (6-
OST) and 3-O-sulfotransferase (3-OST) add sulfo groups at the 6-OH position and 3-OH of 
glucosamine residues, respectively [55].
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Figure 4. Synthetic strategy for N-sulfation step
The N-trifluoroacetyl group of unnatural sugar, UDP-N-trifluoroacetyl glucosamine (UDP-
GlcNTFA), can be converted to GlcNH2 by lithium hydroxide (LiOH). The addition of a 
sulfo group can be achieved by NST and PAPS. NDST = N-deacetylase/N-sulfotransferase, 
NDase = N-deacetylase, NST = N-sulfotransferase, PAPS = 3’-phosphoadenosine-5’-
phosphosulfate.
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Figure 5. Chemoenzymtically synthetic scheme of LMWH
(A)A series of homogeneous synthetic LMWHs designed for improving sensitivity to 
protamine neutralization as well as hepatic clearance. All synthetic LMWHs are structurally 
similar and carry a pentasaccharide domain for AT binding (B) In vitro synthesis of LMWH 
includes 2 steps (i) sugar backbone synthesis and (ii) sugar backbone modification. The 
scheme indicates the implemented strategies to improve the synthetic method. The backbone 
synthesis starts from the elongation of GlcA-pNP using bacterial glycosyltransferase; KfiA 
and pmHS2 to transfer glucosamine and glucoronic acid residues to an acceptor substrate, 
respectively. The addition of sulfo groups to the sugar backbone starts from the N-sulfation 
followed by epimerization, 2-O-, 6-O- and 3-O-sulfo modifications. (57). pNP = para-
nitrophenyl.
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Table 1
Characteristics of the three forms of heparins, CPB = cardio pulmonary bypass, DVT = deep venous 
thrombosis, VTE = vascular thromboembolism, MI = myocardial infarction, AF = atrial fibrillation, HIT = 
heparin-induced thrombocytopenia, ACS = acute coronary syndrome, PE = pulmonary embolism.
Characteristics Unfractionated
heparin
(UFH)
Low molecular-weight
heparin (LMWH)
Ultra low molecular-
weight heparin
(ULMWH)
Classification Full-length
polysaccharide
Fragmented
oligosaccharides
Chemically synthetic
pentasaccharide
M.W. (Dalton) ~14,000 ~6,000 1728
Numbers of sugar
residue
30-40 4-22 5
Source Natural product
(obtained from porcine
intestine and bovine
lung)
Natural product
(chemical or enzymatic
depolymerization of
UFH)
Chemical synthesis
Indication Surgery, CPB, kidney
dialysis, VTE
DVT, VTE, MI,
Unstable angina
ACS, DVT, PE
Mechanism of action Binds to antithrombin and inhibits factor Xa and thrombin (FIIa)
Anti FXa/Anti FIIa 1/1 2-4/1 1/0
Route of
administration
IV or SC SC SC
Hal life (hours) 0.5-1 3-6 15-20
Clearance Liver Kidney Kidney
Incident of HIT
(among three forms)
high Lower than UFH Lowest
Antidote Protamine Protamine (partial) Recombinant factor
VIIa
Precaution in kidney- No Dose-adjustment Yes
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